XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Schedule of Contractual Clinical Trials (Details)
 6 Months Ended
Jun. 30, 2024
USD ($)
Integer
Other Commitments [Line Items]  
Remaining financial contractual commitment | $ $ 3,467,000
Phase 1b [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with atezolizumab in microsatellite stable metastatic colon cancer
Estimated Start Date September 2024
Estimated End Date December 2026
Number of Patients in Trial | Integer 37
Expected Date June 2026
Remaining financial contractual commitment | $ [1]
Phase 1b Two [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with doxorubicin in advanced soft tissue sarcoma
Estimated Start Date June 2023
Estimated End Date Recruitment completed June 2024
Expected Date December 2024
Remaining financial contractual commitment | $ $ 267,000
Phase 1b Two [Member] | Minimum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial | Integer 9
Phase 1b Two [Member] | Maximum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial | Integer 18
Randomized Phase 2 [Member]  
Other Commitments [Line Items]  
Clinical trial, description Doxorubicin with or without LB-100 in advanced soft tissue sarcoma (Randomized
Number of Patients in Trial | Integer 150
Expected Date December 2026
Remaining financial contractual commitment | $ $ 3,200,000
Clinical Trial Phase MD 1b 2 [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with dostarlimab in ovarian clear cell carcinoma
Estimated Start Date January 2024
Estimated End Date December 2027
Number of Patients in Trial | Integer 21
Expected Date December 2026
Remaining financial contractual commitment | $ [1]
[1] The Company has no financial contractual commitment associated with this clinical trial at June 30, 2024.